Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 5/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27496395 | 0.91 | MMP8 (0.51) | MMP8NAMPTCDC7DBF4TSHR | |
| SCHEMBL23832254 | 0.91 | MMP8 (0.47) | MMP8NAMPTCDC7DBF4TSHR | |
| SCHEMBL5141949 | 0.88 | MMP8 (0.45) | MMP8NAMPTCDC7DBF4TSHR | |
| SCHEMBL271585 | 0.86 | MMP8 (0.59) | MMP8TSHRKMT2AMEN1NPC1 | |
| SCHEMBL5143810 | 0.85 | MMP8 (0.47) | MMP8NAMPTCDC7DBF4TSHR | |
| SCHEMBL13228075 | 0.84 | NAMPT (0.44) | MMP8NAMPTKMT2AMEN1NPC1 | |
| SCHEMBL29705753 | 0.84 | ALDH1A1 (0.51) | MMP8NAMPTTSHRKMT2AMEN1 | |
| SCHEMBL755729 | 0.83 | CYP19A1 (0.54) | NAMPTCDC7DBF4TSHRKMT2A | |
| SCHEMBL17086147 | 0.81 | NAMPT (0.44) | MMP8NAMPTCDC7DBF4KMT2A | |
| SCHEMBL28532831 | 0.81 | CYP19A1 (0.49) | NAMPTCDC7DBF4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-07-30 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
| CN-104892528-A | A preparing method of 2-thiobarbituric acid derivatives | UNIV SHANGHAI ENG SCIENCE | 2015-09-09 | — | — | CN | disclosed |
| EP-1343786-B1 | NOVEL PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1499369-A1 | STENTS CONTAINING PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2005-01-26 | — | — | EP | disclosed |
| CN-1555374-A | Novel pyridine substituted pyrazolopyridine derivatives | — | 2004-12-15 | — | — | CN | disclosed |
| US-6693102-B2 | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-17 | — | — | US | disclosed |
| WO-2003089024-A1 | STENTS CONTAINING PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003086407-A1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING GLAUCOMA | BAYER HEALTHCARE AG (DE) | 2003-10-23 | — | — | WO | disclosed |
| EP-1343786-A1 | NOVEL PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002042301-A1 | NOVEL PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| US-5908863-A | ANTIGROWTH AGENT FOR BONES | DOMPE' S.P.A. (IT) | 1999-06-01 | — | — | US | disclosed |
| EP-0792878-A2 | Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism | Dompé S.P.A. (IT) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | SOD1, AOC3, CBR3 | MMP8 4481/4885NAMPT 886/4885CDC7 3525/4885 |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | GUCY1A1, GUCY1A2, GUCY1B1 | MMP8 3120/4885NAMPT 2698/4885CDC7 2356/4885 |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | SOD1, AOC3, CBR3 | MMP8 4481/4885NAMPT 886/4885CDC7 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.